Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof

摘要

Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases characterized by aberrant DLL4 and/or VEGF expression or activity.

主权项

1. A method of treating a disease characterized by elevated DLL4 and/or VEGF expression or activity in a subject, comprising administering a binding protein or a pharmaceutical composition comprising the binding protein to a subject in need thereof, wherein the binding protein comprises first and second polypeptide chains, each independently comprising VD1-(X1)n-VD2-C-(X2)n, wherein
VD1 is a first variable domain; VD2 is a second variable domain; C is a constant domain; X1 is a linker; X2 is an Fc region; n is 0 or 1,wherein the VD1 domains on the first and second polypeptide chains form a first functional target binding site and the VD2 domains on the first and second polypeptide chains form a second functional target binding site, and wherein the binding protein is capable of binding DLL4 and VEGF, wherein the first polypeptide chain of the binding protein comprises SEQ ID NO: 56 and the second polypeptide chain of the binding protein comprises SEQ ID NO: 64.